TScan Therapeutics Announces Updates to its Board of Directors
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as […]
Plymouth Industrial REIT Declares Dividend for the Second Quarter of 2024
BOSTON, June 14, 2024 (GLOBE NEWSWIRE) — Plymouth Industrial REIT, Inc. (NYSE: PLYM) (the “Company”) today announced that its board […]
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people […]
Brookfield Business Partners L.P. 2024 Second Quarter Conference Call and Webcast for Investors and Analysts
Date: Friday, August 2, 2024 Time: 10:00 a.m. (Eastern Time) BROOKFIELD NEWS, June 14, 2024 (GLOBE NEWSWIRE) — You are invited […]
Virginia529 Selects eGain AI Knowledge to Elevate Customer and Advisor Experience
SUNNYVALE, Calif., June 14, 2024 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading AI knowledge platform for customer service, today […]
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete […]
The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share
SAN JUAN CAPISTRANO, Calif., June 14, 2024 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group […]
Greenwich LifeSciences Announces $2.5 Million Private Placement
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company” or “Greenwich”), a clinical-stage biopharmaceutical […]
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization […]
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) […]
